Biosimilars are a relatively new category of medications that have emerged as a promising alternative to biologic drugs. These complex molecules are designed to be highly similar to an already approved biologic, known as the reference product. The introduction of biosimilars has generated significant interest due to their potential to reduce healthcare costs and increase access to important therapies. However, questions about their safety and effectiveness remain at the forefront of discussions among healthcare providers, patients, and policymakers.

To fully appreciate the role of biosimilars, it is essential to understand what they are and how they differ from traditional generic drugs. Unlike small-molecule generics, which are chemically synthesized and identical to their brand-name counterparts, biosimilars are derived from living organisms and are not exact copies. This is because biologics themselves are large, complex molecules produced through intricate biological processes. As a result, biosimilars are similar but not identical to their reference products, which necessitates a rigorous approval process to ensure they meet stringent standards of quality, safety, and ef...